416 related articles for article (PubMed ID: 6801981)
1. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
Kay CR
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):762-5. PubMed ID: 6801981
[TBL] [Abstract][Full Text] [Related]
2. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
Wilson ES; Cruickshank J; McMaster M; Weir RJ
Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
[TBL] [Abstract][Full Text] [Related]
3. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
4. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
[TBL] [Abstract][Full Text] [Related]
5. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
7. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
8. Progestogen-only microdose followed by estrogen-progestogen combination, a new approach to oral contraception.
Russowsky M; Sartoretto JN
Contraception; 1982 Jul; 26(1):41-9. PubMed ID: 7128133
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
10. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
11. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
12. Progestogen effects and their relationship to lipoprotein changes. A report from the Oral Contraception Study of the Royal College of General Practitioners.
Wingrave SJ
Acta Obstet Gynecol Scand Suppl; 1982; 105():33-6. PubMed ID: 6805242
[TBL] [Abstract][Full Text] [Related]
13. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
Wynn V; Niththyananthan R
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
[TBL] [Abstract][Full Text] [Related]
14. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
Derman RJ
Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptive agents.
Shearman RP
Med J Aust; 1986 Feb; 144(4):201-5. PubMed ID: 3945219
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.
Contraception; 1980 May; 21(5):445-59. PubMed ID: 7428356
[TBL] [Abstract][Full Text] [Related]
18. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses.
Krauss RM; Roy S; Mishell DR; Casagrande J; Pike MC
Am J Obstet Gynecol; 1983 Feb; 145(4):446-52. PubMed ID: 6401927
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
